YOLFTbeta
AbbVie Inc

AbbVie Inc

ABBV · NYSE · Healthcare / Drug Manufacturers - General

295.03USD+0.58 (+0.20%)

Price History

Full chart

Market Stats

Previous Close294.45
Open296.58
Day Range293.56 – 297.25
52-Week Range188.25 – 302.93
Volume3.19M
Market Cap509.50B
P/E (TTM)49.53
Forward P/E18.15
EPS5.82
Dividend Yield2.40%
Beta0.19
50-Day Avg270.78
200-Day Avg238.22

About

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - General
  • CEOMr. Robert A. Michael CPA
  • Employees57.00K
  • Headquarters1 North Waukegan Road, North Chicago, IL, United States, 60064-6400, USA
  • Websitehttps://www.abbvie.com

Leadership

  • Mr. Robert A. Michael CPACEO & Chairman of the Board · b. 1970
  • Mr. Scott T. ReentsExecutive VP & CFO · b. 1967
  • Dr. Azita Saleki Ph.D.Executive VP & COO · b. 1963
  • Dr. Roopal B. Thakkar M.D.Executive VP of Research & Development and Chief Scientific Officer · b. 1972
  • Mr. Jeffrey Ryan StewartExecutive VP & Chief Commercial Officer · b. 1969
  • Ms. Linda RaySenior VP & Chief Information Officer
  • Ms. Elizabeth SheaSenior Vice President of Investor Relations
  • Mr. Perry C. SiatisExecutive VP, General Counsel & Secretary · b. 1975
  • Mr. Demetris D. CrumExecutive VP & Chief Human Resources Officer · b. 1981
  • Mr. Wulff-Erik von BorckeSenior VP & President of Oncology

Financials

Income Statement

Currency: USD2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue14.21B15.64B17.44B18.38B18.79B19.96B22.86B25.64B28.22B32.75B33.27B45.80B56.20B58.05B54.32B56.33B61.16B
Growth (%)-+10.02%+11.55%+5.37%+2.23%+6.23%+14.52%+12.16%+10.06%+16.08%+1.57%+37.69%+22.69%+3.30%-6.44%+3.71%+8.57%
Cost of Revenue4.06B4.29B4.64B4.51B4.58B4.43B4.50B5.83B7.04B7.72B7.44B15.39B17.45B17.41B20.41B16.90B18.20B
Gross Profit10.16B11.35B12.80B13.87B14.21B15.53B18.36B19.80B21.18B25.04B25.83B30.42B38.75B40.64B33.90B39.43B42.96B
Gross Margin71.46%72.55%73.41%75.47%75.62%77.83%80.31%77.25%75.05%76.44%77.64%66.41%68.96%70.00%62.42%69.99%70.24%
Operating Expense5.23B6.63B9.19B8.05B8.54B12.12B10.82B10.46B11.63B18.65B12.84B19.05B20.83B22.52B21.15B30.29B22.86B
Operating Income4.93B4.72B3.62B5.82B5.66B3.41B7.54B9.34B9.54B6.38B12.98B11.36B17.92B18.12B12.76B9.14B20.09B
Operating Margin34.70%30.16%20.75%31.65%30.14%17.09%32.97%36.43%33.83%19.49%39.03%24.81%31.89%31.21%23.49%16.22%32.85%
EBITDA5.80B6.02B4.94B6.98B6.53B3.58B8.20B10.12B10.38B8.31B12.23B12.32B23.93B24.17B17.17B14.91B17.63B
EBITDA Margin40.80%38.50%28.32%37.97%34.74%17.96%35.87%39.47%36.78%25.37%36.76%26.90%42.59%41.64%31.61%26.47%28.82%
Net Income4.64B4.18B3.43B5.28B4.13B1.77B5.14B5.95B5.31B5.69B7.88B4.62B11.54B11.84B4.86B4.28B4.23B
Net Income Margin32.62%26.72%19.68%28.70%21.97%8.89%22.50%23.22%18.82%17.36%23.69%10.08%20.54%20.39%8.95%7.59%6.91%
R&D1.71B2.81B3.29B3.07B3.19B3.65B4.43B4.58B5.33B10.75B6.79B7.75B8.05B6.51B7.67B12.79B9.10B
R&D as % of Total Revenue12.01%17.96%18.87%16.68%16.99%18.28%19.40%17.88%18.90%32.83%20.42%16.93%14.32%11.21%14.13%22.71%14.87%
Interest Expense000104.00M299.00M429.00M719.00M1.05B1.15B1.35B1.78B2.45B2.42B2.23B2.22B2.81B2.89B
Interest Expense % of Total Revenue0.00%0.00%0.00%0.57%1.59%2.15%3.15%4.08%4.08%4.12%5.36%5.36%4.31%3.84%4.09%4.98%4.73%

Balance Sheet

Currency: USD2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets-21.13B19.52B27.01B29.20B27.51B53.05B66.10B70.79B59.35B89.11B150.56B146.53B138.81B134.71B135.16B133.96B
Total Liabilities-5.43B7.59B23.64B24.71B25.77B49.10B61.46B65.69B67.80B97.29B137.47B131.09B121.52B124.31B131.80B137.19B
Total Equity-15.70B11.93B3.36B4.49B1.74B3.94B4.64B5.10B-8.45B-8.17B13.10B15.44B17.29B10.40B3.36B-3.23B
Cash-9.64M27.00M5.90B9.60B8.35B8.40B5.10B9.30B7.29B39.92B8.45B9.75B9.20B12.81B5.52B5.23B
Total Debt--48.00M15.67B14.72B15.01B31.67B36.84B37.37B40.31B67.09B87.06B77.58B64.19B60.12B67.84B69.07B
Net Debt--1.88B-27.48M9.77B5.13B6.66B23.27B31.74B28.07B33.02B27.16B78.61B67.83B54.99B47.31B62.32B63.84B

Cash Flow

Currency: USD2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow5.37B4.98B6.25B6.34B6.27B3.55B7.54B7.04B9.96B13.43B13.32B17.59B22.78B24.94B22.84B18.81B19.03B
Investing Cash Flow-486.36M-5.03B553.90M-2.42B879.00M-926.00M-12.94B-6.07B-274.00M-1.01B596.00M-37.56B-2.34B-623.00M-2.01B-20.82B-6.64B
Financing Cash Flow-4.88B65.00M-6.78B1.93B-3.44B-3.29B5.75B-3.93B-5.51B-14.40B18.71B-11.50B-19.04B-24.80B-17.22B-5.21B-12.72B
Capital Expenditure312.56M448.00M355.51M333.00M491.00M612.00M532.00M479.00M529.00M638.00M552.00M798.00M787.00M695.00M777.00M974.00M1.21B
Free Cash Flow5.05B4.53B5.89B6.01B5.78B2.94B7.00B6.56B9.43B12.79B12.77B16.79B21.99B24.25B22.06B17.83B17.82B
Dividends Paid----2.56B2.66B3.29B3.72B4.11B5.58B6.37B7.72B9.26B10.04B10.54B11.03B11.66B
FCF to OCF94.18%91.00%94.31%94.75%92.17%82.76%92.94%93.20%94.69%95.25%95.86%95.46%96.54%97.21%96.60%94.82%93.62%
Dividend Paid to FCF----44.23%90.60%47.04%56.64%43.55%43.63%49.84%45.96%42.11%41.42%47.77%61.83%65.43%

Earnings

Report DateJan 23, 2013Apr 26, 2013Jul 26, 2013Oct 25, 2013Jan 31, 2014Apr 25, 2014Jul 25, 2014Oct 31, 2014Jan 30, 2015Apr 23, 2015Jul 24, 2015Oct 30, 2015Jan 29, 2016Apr 28, 2016Jul 29, 2016Oct 28, 2016Jan 27, 2017Apr 27, 2017Jul 28, 2017Oct 27, 2017Jan 26, 2018Apr 26, 2018Jul 27, 2018Nov 2, 2018Jan 25, 2019Apr 25, 2019Jul 26, 2019Nov 1, 2019Feb 7, 2020May 1, 2020Jul 31, 2020Oct 30, 2020Feb 3, 2021Apr 30, 2021Jul 30, 2021Oct 29, 2021Feb 2, 2022Apr 29, 2022Jul 29, 2022Oct 28, 2022Feb 9, 2023Apr 27, 2023Jul 27, 2023Oct 27, 2023Feb 2, 2024Apr 26, 2024Jul 25, 2024Oct 30, 2024Jan 31, 2025Apr 25, 2025Jul 31, 2025Oct 31, 2025Feb 4, 2026Apr 29, 2026Jul 31, 2026Oct 30, 2026
EPS Estimate0.990.670.790.770.820.680.760.770.860.851.061.081.121.141.201.201.201.261.401.391.431.791.972.001.932.072.212.302.192.252.202.772.852.833.033.223.283.143.313.573.582.492.812.872.772.232.662.922.122.402.911.782.652.673.643.74
EPS Actual0.980.680.820.820.820.710.820.890.890.941.081.131.131.151.261.211.201.281.421.411.481.872.002.141.902.142.262.332.212.422.342.832.922.953.113.333.313.163.373.663.602.462.912.952.792.312.653.002.162.462.971.862.712.653.653.82
Surprise-1.40%1.49%3.80%6.49%0.00%4.41%7.89%15.58%3.49%10.59%1.89%4.63%0.89%0.88%5.00%0.83%0.00%1.59%1.43%1.44%3.50%4.47%1.52%7.00%-1.55%3.38%2.26%1.30%0.91%7.56%6.36%2.17%2.46%4.24%2.64%3.42%0.91%0.64%1.81%2.52%0.56%-1.20%3.56%2.79%0.72%3.59%-0.38%2.74%1.89%2.50%2.06%4.49%2.26%-0.75%0.27%2.14%
Timing-Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap509.50B
Enterprise Value579.63B
Trailing P/E49.53
Forward P/E18.15
PEG Ratio0.59
Price / Sales7.72
Price / Book245.29
EPS5.82
Book Value-2.59
Revenue (TTM)66.01B
Gross Profit (TTM)48.67B
EBITDA31.85B
Profit Margin15.67%
Operating Margin39.59%
Return on Equity62.25%
Return on Assets10.74%
Shares Outstanding1.77B
Shares Float1.76B
Beta0.19
Dividend Yield2.40%
Dividend Rate6.92
Payout Ratio53.94%

Analyst Ratings

Buy
Based on 29 analystsTarget 306.42
  • Strong Buy
    16
  • Buy
    7
  • Hold
    5
  • Sell
    1

Ownership Breakdown

Institutions
77.18%
Insiders
0.11%
Retail / Other
22.71%

Top Institutional Holders

  • BlackRock Inc
    149.49M8.46%
  • Vanguard Capital Management, LLC
    115.40M6.53%
  • State Street Corp
    82.60M4.67%
  • Vanguard Portfolio Management, LLC
    48.48M2.74%
  • JPMorgan Chase & Co
    47.86M2.71%
  • Geode Capital Management, LLC
    47.00M2.66%
  • Morgan Stanley - Brokerage Accounts
    38.90M2.20%
  • Capital Research Global Investors
    30.10M1.70%
  • NORGES BANK
    25.55M1.45%
  • Bank of America Corp
    21.24M1.20%
  • FMR Inc
    20.77M1.18%
  • Northern Trust Corp
    20.56M1.16%
  • Franklin Templeton Inc
    19.93M1.13%
  • Capital World Investors
    19.18M1.09%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    56.10M3.17%
  • Vanguard 500 Index Investor
    46.41M2.63%
  • iShares Core S&P 500 ETF
    23.51M1.33%
  • Fidelity 500 Index
    22.93M1.30%
  • State Street® SPDR® S&P 500® ETF
    21.61M1.22%
  • Vanguard MStar Value Index Investor
    16.83M0.95%

Dividends

20264×
1.73Oct 15, 20261.73Jul 15, 20261.73Apr 15, 20261.73Jan 16, 2026
20254×
1.64Oct 15, 20251.64Jul 15, 20251.64Apr 15, 20251.64Jan 15, 2025
20244×
1.55Oct 15, 20241.55Jul 15, 20241.55Apr 12, 20241.55Jan 12, 2024
20234×
1.48Oct 12, 20231.48Jul 13, 20231.48Apr 13, 20231.48Jan 12, 2023
20224×
1.41Oct 13, 20221.41Jul 14, 20221.41Apr 13, 20221.41Jan 13, 2022
20214×
1.30Oct 14, 20211.30Jul 14, 20211.30Apr 14, 20211.30Jan 14, 2021